新闻

2020-11-06

挚盟医药完成2.3亿元A轮融资，助力推进乙肝治疗产品的临床研究和加速后续在研产品的临床转化

2020-03-05

挚盟医药宣布完成乙肝新药美国临床I期首次人体给药

2020-01-19

挚盟医药抗乙肝病毒核衣壳抑制剂ZM-H1505R获美国FDA临床试验许可

2019-11-13

挚盟医药完成近亿元Pre-A轮融资，开发乙肝和中枢神经疾病治疗新药

2019-02-21

Zhimeng Biopharma announces that it will present new anti-HBV data on its novel hepatitis B virus (HBV) nucleocapsid formation inhibitor CB-001 at the EASL-AASLD Joint Meeting on HBV Endpoints in London, March 8-9, 2019

2018-11-09

Zhimeng Biopharma presented the discovery and efficacy data of its novel hepatitis B virus (HBV) nucleocapsid formation inhibitor CB-001 at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco

快速链接

联系我们关于我们领导团队管理团队科学顾问